Evidence map›Paper›PMID 41568436›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction

Wanling Wu, Shudan Yang, Jie Liu, Yuting Wang, Defeng Pan, Yafeng Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wanling WuDepartment of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
Shudan YangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Jie LiuDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yuting WangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.
Defeng PanDepartment of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yafeng ZhouDepartment of Cardiology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The PCSK9-LDLR interaction, driving elevated LDL-C, is a key driver of ASCVD pathogenesis. Identifying peptides disrupting this interaction offers an alternative ASCVD therapy. Herein,

Indexed as

Molecular Dynamics SimulationPCSK9 InhibitorsPeptidesProprotein Convertase 9Receptors, LDLAnimalsDose-Response Relationship, DrugDrug Evaluation, PreclinicalHep G2 CellsHumansMiceMolecular StructurePharmacophoreProtein BindingStructure-Activity RelationshipLDLR protein, humanPCSK9 InhibitorsPCSK9 protein, humanPeptidesProprotein Convertase 9Receptors, LDLatherosclerotic cardiovascular diseasePCSK9peptide inhibitorpharmacophore-based virtual screeningprotein–protein interaction

Identifiers

PMID41568436
PMCPMC12829418

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.